Lobar Distribution of Low Grade Oligodendroglioma: Distribution, Molecular Characteristics, and Survival Based upon Location

Donald A. Ross^*, Shao Tao, Sakir Gultekin, Amy M. Ross

Portland Veterans Medical Center, Oregon Health & Science University, Portland, Oregon, USA.

DOI: 10.4236/jct.2014.513126                

Abstract

Grade II oligodendrogliomas are rare and slow growing tumors, making long-term follow up difficult, but necessary for better understanding. In this retrospective study a review of all grade II oligodendrogliomas encountered in the last 20 years at one institution, was undertaken to determine if specific tumor location and immunohistochemical analysis had any impact on recurrence rate, progression free survival, or life expectancy. Eighty-nine grade II oligodendroglioms cases were reviewed (38 females and 51 males; mean age was 40.3 ± 13.8 years). Tumor location was: frontal lobe (44, 49.4%) and superior frontal gyrus (30, 33.7%). 1p19q data were available in 49 patients. Twenty-nine cases were co-deleted (59.2%). There was no significant difference in the incidence of 1p19q co-deletion between superior frontal gyrus tumors vs. other frontal tumors or extra-frontal tumors (p = 0.45). Follow up of at least 3 months after diagnosis was available in 79 patients (mean follow up: 93.2 months). In recurrence analysis, recurrence by 1p19q status and recurrence by location revealed no significant differences. In analysis of progression, progression by 1p19q status and progression by location revealed no significant differences. An analysis of deaths for the sample, deaths by 1p19q status and deaths by location revealed no significant differences. There was a higher death rate among patients >50 years of age, however this, too, was not significant. There did not appear to be any advantage in recurrence rate, progression free survival, or life expectancy for tumors located in the frontal lobe or superior frontal gyrus. 1p19q co-deletion did not appear to confer an advantage as measured by time to recurrence, time to progression, or overall survival. Other than age, eloquent location, Karnofsky status, and overall tumor size as reported by others, tumor location and 1p19q status in low grade oligodendrogliomas are not currently predictive of survival.

Keywords

Grade II Oligodendrogliomas, Frontal Lobe, Superior Frontal Gyrus, 1p19q, Isocitrate Dehydrogenase 1

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Ross, D., Yang, L., Sagher, O. and Ross, A. (2011) Radical Resection of Adult Low Grade Oligodendroglioma without Adjuvant Therapy: Results of a Prospective Treatment Protocol-Surgical Treatment of Low-Grade Oligodendroglioma. Journal of Cancer Therapy, 2, 235-242. http://dx.doi.org/10.4236/jct.2011.22030
[2]	Louis, D., Ohgaki, H., Wiestler, O. and Cavenee, W. (2007) World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Nervous System. WHO Press, Lyon.
[3]	Okamoto, Y., Di Patre, P.L., Burkhard, C., Horstmann, S., Jourde, B., Fahey, M., et al. (2004) Population-Based Study on Incidence, Survival Rates, and Genetic Alterations of Low-Grade Diffuse Astrocytomas and Oligodendrogliomas. Acta Neuropathologica, 108, 49-56. http://dx.doi.org/10.1007/s00401-004-0861-z
[4]	Alentorn, A., Sanson, M. and Idbaih, A. (2012) Oligodendrogliomas: New Insights from the Genetics and Perspectives. Current Opinion in Oncology, 24, 687-693. http://dx.doi.org/10.1097/CCO.0b013e328357f4ea
[5]	Bourne, T.D. and Schiff, D. (2010) Update on Molecular Findings, Management and Outcome in Low-Grade Gliomas. Nature Reviews Neurology, 6, 695-701. http://dx.doi.org/10.1038/nrneurol.2010.159
[6]	Rodriguez, F.J. and Giannini, C. (2010) Oligodendroglial Tumors: Diagnostic and Molecular Pathology. Seminars in Diagnostic Pathology, 27, 136-145. http://dx.doi.org/10.1053/j.semdp.2010.05.001
[7]	Sanai, N., Chang, S. and Berger, M.S. (2011) Low-Grade Gliomas in Adults. Journal of Neurosurgery, 115, 948-965. http://dx.doi.org/10.3171/2011.7.JNS101238
[8]	van den Bent, M.J., Snijders, T.J. and Bromberg, J.E. (2012) Current Treatment of Low Grade Gliomas. Memo, 5, 223-227. http://dx.doi.org/10.1007/s12254-012-0014-3
[9]	Chang, E.F., Clark, A., Smith, J.S., Polley, M.Y., Chang, S.M., Barbaro, N.M., et al. (2011) Functional Mapping-Guided Resection of Low-Grade Gliomas in Eloquent Areas of the Brain: Improvement of Long-Term Survival. Journal of Neurosurgery, 114, 566-573. http://dx.doi.org/10.3171/2010.6.JNS091246
[10]	Snyder, L.A., Wolf, A.B., Oppenlander, M.E., Bina, R., Wilson, J.R., Ashby, L., et al. (2014) The Impact of Extent of Resection on Malignant Transformation of Pure Oligodendrogliomas. Journal of Neurosurgery, 120, 309-314. http://dx.doi.org/10.3171/2013.10.JNS13368
[11]	Capelle, L., Fontaine, D., Mandonnet, E., Taillandier, L., Golmard, J.L., Bauchet, L., et al. (2013) Spontaneous and Therapeutic Prognostic Factors in Adult Hemispheric World Health Organization Grade II Gliomas: A Series of 1097 Cases: Clinical Article. Journal of Neurosurgery, 118, 1157-1168. http://dx.doi.org/10.3171/2013.1.JNS121
[12]	Marko, N.F. and Weil, R.J. (2013) The Molecular Biology of WHO Grade II Gliomas. Neurosurgical Focus, 34, E1. http://dx.doi.org/10.3171/2012.12.FOCUS12283
[13]	Riemenschneider, M.J. and Reifenberger, G. (2010) Molecular Neuropathology of Low-Grade Gliomas and Its Clinical Impact. Advances and Technical Standards in Neurosurgery, 35, 35-64. http://dx.doi.org/10.1007/978-3-211-99481-8_2
[14]	Brain Health and Puzzles (2012) Fun Facts about the Brain. http://www.brainhealthandpuzzles.com/fun_facts_about_the_brain.html
[15]	El-Hateer, H., Souhami, L., Roberge, D., Maestro, R.D., Leblanc, R., Eldebawy, E., et al. (2009) Low-Grade Oligodendroglioma: An Indolent but Incurable Disease? Journal of Neurosurgery, 111, 265-271. http://dx.doi.org/10.3171/2008.11.JNS08983
[16]	Zlatescu, M.C., Tehrani Yazdi, A., Sasaki, H., Megyesi, J.F., Betensky, R.A., Louis, D.N. and Cairncross, J.G. (2001) Tumor Location and Growth Pattern Correlate with Genetic Signature in Oligodendroglial Neoplasms. Cancer Research, 61, 6713-6715.
[17]	Chang, E.F., Smith, J.S., Chang, S.M., Lamborn, K.R., Prados, M.D., Butowski, N., et al. (2008) Preoperative Prognostic Classification System for Hemispheric Low-Grade Gliomas in Adults. Journal of Neurosurgery, 109, 817-824. http://dx.doi.org/10.3171/JNS/2008/109/11/0817
[18]	Thon, N., Eigenbrod, S., Grasbon-Frodl, E.M., Ruiter, M., Mehrkens, J.H., Kreth, S., Tonn, J.C., Kretzschmar, H.A. and Kreth, F. (2009) Novel Molecular Stereotactic Biopsy Procedures Reveal Intratumoral Homogeneity of Loss of Heterozygosity of 1p/19q and TP53 Mutations in World Health Organization Grade II Gliomas. Journal of Neuropathology & Experimental Neurology, 68, 1219-1228. http://dx.doi.org/10.1097/NEN.0b013e3181bee1f1
[19]	Megyesi, J.F., Kachur, E., Lee, D.H., Zlatescu, M.C., Betensky, R.A., Forsyth, P.A., et al. (2004) Imaging Correlates of Molecular Signatures in Oligodendrogliomas. Clinical Cancer Research, 10, 4303-4306. http://dx.doi.org/10.1158/1078-0432.CCR-04-0209
[20]	Jenkinson, M.D., du Plessis, D.G., Smith, T.S., Joyce, K.A., Warnke, P.C. and Walker, C. (2006) Histological Growth Patterns and Genotype in Oligodendroglial Tumours: Correlation with MRI Features. Brain, 129, 1884-1891. http://dx.doi.org/10.1093/brain/awl108
[21]	Brown, R., Zlatescu, M., Sijben, A., Roldan, G., Easaw, J., Forsyth, P., et al. (2008) The Use of Magnetic Resonance Imaging to Noninvasively Detect Genetic Signatures in Oligodendroglioma. Clinical Cancer Research, 14, 2357-2362. http://dx.doi.org/10.1158/1078-0432.CCR-07-1964
[22]	Capelle, L., Oei, P., Teoh, H., Hamilton, D., Palmer, D., Low, I. and Campbell, G. (2009) Retrospective Review of Prognostic Factors, Including 1p19q Deletion, in Low-Grade Oligodendrogliomas and a Review of Recent Published Works. Journal of Medical Imaging and Radiation Oncology, 53, 305-309. http://dx.doi.org/10.1111/j.1754-9485.2009.02074.x
[23]	Kesari, S., Schiff, D., Drappatz, J., LaFrankie, D., Doherty, L., Macklin, E.A., et al. (2009) Phase II Study of Protracted Daily Temozolomide for Low-Grade Gliomas in Adults. Clinical Cancer Research, 15, 330-337. http://dx.doi.org/10.1158/1078-0432.CCR-08-0888
[24]	Tosoni, A., Franceschi, E., Ermani, M., Bertorelle, R., Bonaldi, L., Blatt, V. and Brandes, A.A. (2008) Temozolomide Three Weeks on and One Week off as First Line Therapy for Patients with Recurrent or Progressive Low Grade Gliomas. Journal of Neuro-Oncology, 89, 179-185. http://dx.doi.org/10.1007/s11060-008-9600-y
[25]	Roth, P., Wick, W. and Weller, M. (2013) Anaplastic Oligodendroglioma: A New Treatment Paradigm and Current Controversies. Current Treatment Options in Oncology, 14, 505-513. http://dx.doi.org/10.1007/s11864-013-0251-7
[26]	Gorlia, T., Delattre, J.Y., Brandes, A.A., Kros, J.M., Taphoorn, M.J., Kouwenhoven, M.C., et al. (2013) New Clinical, Pathological and Molecular Prognostic Models and Calculators in Patients with Locally Diagnosed Anaplastic Oligodendroglioma or Oligoastrocytoma. A Prognostic Factor Analysis of European Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European Journal of Cancer, 49, 3477-3485. http://dx.doi.org/10.1016/j.ejca.2013.06.039
[27]	Goze, C., Mansour, L., Rigau, V. and Duffau, H. (2013) Distinct IDH1/IDH2 Mutation Profiles in Purely Insular versus Paralimbic WHO Grade II Gliomas. Journal of Neurosurgery, 118, 866-872. http://dx.doi.org/10.3171/2012.11.JNS121100
[28]	Dubbink, H.J., Taal, W., van Marion, R., Kros, J.M., van Heuvel, I., Bromberg, J.E., et al. (2009) IDH1 Mutations in Low-Grade Astrocytomas Predict Survival but Not Response to Temozolomide. Neurology, 73, 1792-1795. http://dx.doi.org/10.1212/WNL.0b013e3181c34ace
[29]	Labussiere, M., Idbaih, A., Wang, X.W., Marie, Y., Boisselier, B., Falet, C., et al. (2010) All the 1p19q Codeleted Gliomas Are Mutated on IDH1 or IDH2. Neurology, 74, 1886-1890. http://dx.doi.org/10.1212/WNL.0b013e3181e1cf3a